Physician profile
Arthur E Vandyke
NPI 1346234036
$4,550.38
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $796 · 2020: $484 · 2021: $708 · 2022: $805 · 2023: $861 · 2024: $897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,757.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,500.61 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $429.21 | 2019-2024 | Eliquis, Camzyos |
| Pfizer INC. | $352.21 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $289.44 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $267.84 | 2019-2024 | Farxiga, Brilinta, Wainua |
| Amgen INC. | $264.94 | 2019-2024 | Repatha |
| Merck Sharp & Dohme LLC | $249.12 | 2021-2024 | Verquvo |
| Boston Scientific Corporation | $199.91 | 2019-2024 | Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $186.89 | 2020-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $135.83 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $103.85 | 2019-2022 | |
| Esperion Therapeutics, INC. | $102.45 | 2020-2024 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $91.46 | 2019 | |
| Impulse Dynamics (USA) INC. | $55.81 | 2020 | |
| Scpharmaceuticals INC. | $46.24 | 2023-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $40.02 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $39.91 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $35.69 | 2024 | Arcalyst |
| Philips North America LLC | $35.22 | 2020-2022 | |
| Alnylam Pharmaceuticals INC. | $23.70 | 2021-2022 | |
| Abbott Laboratories | $22.83 | 2020 | |
| Novo Nordisk INC | $17.60 | 2024 | Wegovy |
| Sunovion Pharmaceuticals INC. | $17.05 | 2019 | |
| Portola Pharmaceuticals, LLC | $15.33 | 2019 | |
| Bardy Diagnostics, INC. | $15.00 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Vandyke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.